Acadia Pharmaceuticals (ACAD) PT Raised to $19 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Acadia Pharmaceuticals (ACAD) IP Decision 'Removes a Key Overhang' - BMO Capital
May 16, 2025 11:56 AM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $24.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) saying the IP decision removes a key overhang for ACAD shares Into the 2030s.
The analyst commented, "Positive update for ACAD shares... More
Acadia Pharma (ACAD) Shares Gain After Ruling In Patent Case Vs Aurobindo - Bloomberg
May 16, 2025 10:08 AM EDTAcadia Pharma (NASDAQ: ACAD) Shares Gain After Ruling In Patent Case Vs Aurobindo - Bloomberg
... MoreAcadia Pharmaceuticals (ACAD) PT Raised to $26 at JPMorgan
May 16, 2025 8:49 AM EDTJPMorgan analyst Tessa Romero raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $25.00) while maintaining a Overweight rating.... More
Citizens JMP Reiterates Market Outperform Rating on Acadia Pharmaceuticals (ACAD)
May 14, 2025 4:07 AM EDTCitizens JMP analyst Jason Butler reiterated a Market Outperform rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst commented, Solid quarter with NUPLAZID continuing to excel and robust patient growth for DAYBUE; we reiterate our Market Outperform rating and $37 risk-adjusted, DCF-derived price... More
